Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

doi:10.3389/fonc.2021.657283

	Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study
	Song, Zhengbo 1,2; Lv, Dongqing 3; Chen, Shiqing 4; Huang, Jianhui 5; Wang, Liping 6; Xu, Shuguang 7; Chen, Huafei 8; Wang, Guoqiang 4; Lin, Quan 9
刊名	FRONTIERS IN ONCOLOGY
	2021-05-07
卷号	11
关键词	non-small cell lung cancer (NSCLC) HER2 afatinib efficacy resistance
ISSN号	2234-943X
DOI	10.3389/fonc.2021.657283
通讯作者	Song, Zhengbo(songzhengbo83@163.com) ; Lin, Quan(lquan007@163.com)
英文摘要	Background Non-small cell lung cancer (NSCLC) patients with HER2 mutations and amplification may benefit from HER2-targeted therapy, including afatinib. However, the data regarding the clinical activity of afatinib in Chinese patients with NSCLC harboring HER2 alterations are limited. Patients and methods We retrospectively included metastatic NSCLC patients harboring HER2 alterations who treated with afatinib. The clinical outcomes included overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). The genomic profiling data after progression on afatinib were analyzed. Results We included 54 patients harboring HER2 mutations and 12 patients harboring HER2 amplification. The ORR was 24% (95% CI, 16-36%), the median PFS was 3.3 months (95% CI, 2.2-4.4), and the median OS was 13.9 months (95% CI, 11.4-16.5). Patients with HER2 exon 20 mutations had numerically worse ORR (17% vs 42%), shorter PFS (2.6 vs 5.8 months, HR, 2.5; 95% CI, 1.2-5.5; P = 0.015) and OS (12.9 vs 33.3 months, HR, 4.4; 95% CI, 1.3-14.8; P = 0.009) than patients with other mutations. For HER2-amplified patients, the ORR was 33% (95% CI, 14-61%), the median PFS was 3.3 months (95% CI, 2.6-4.0), and the median OS was 13.4 months (95% CI, 0-27.6). The most frequently mutated genes in afatinib-resistant patients were TP53 (44%) and EGFR (33%). Three afatinib-resistant patients harbored secondary HER2 alterations. Conclusions Our results suggest that afatinib has a promising anti-tumor activity in patients with NSCLC harboring HER2 alterations. To our knowledge, this is the largest retrospective study about the clinical activity of afatinib in NSCLC patients with HER2 alterations.
WOS研究方向	Oncology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000652576900001
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/122677]
专题	中国科学院合肥物质科学研究院
通讯作者	Song, Zhengbo; Lin, Quan
作者单位	1.Univ Chinese Acad Sci, Dept Clin Trail, Canc Hosp, Zhejiang Canc Hos, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 3.Taizhou Hosp, Dept Resp Dis, Taizhou, Peoples R China 4.3D Med Inc, Med Dept, Shanghai, Peoples R China 5.Lishui Ctr Hosp, Dept Med Oncol, Lishui, Peoples R China 6.Baotou Canc Hosp, Dept Med Oncol, Baotou, Peoples R China 7.Lihuili Eastern Hosp, Ningbo Med Ctr, Dept Resp Dis, Ningbo, Zhejiang, Peoples R China 8.Rongjun Hosp, Dept Thorac Dis Ctr, Jiaxing, Peoples R China 9.Wenzhou Med Univ, Dept Pulm Med, Affiliated Hosp 1, Wenzhou, Peoples R China
推荐引用方式 GB/T 7714	Song, Zhengbo,Lv, Dongqing,Chen, Shiqing,et al. Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study[J]. FRONTIERS IN ONCOLOGY,2021,11.
APA	Song, Zhengbo.,Lv, Dongqing.,Chen, Shiqing.,Huang, Jianhui.,Wang, Liping.,...&Lin, Quan.(2021).Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study.FRONTIERS IN ONCOLOGY,11.
MLA	Song, Zhengbo,et al."Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study".FRONTIERS IN ONCOLOGY 11(2021).